This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Muscular dystrophy	Tripartite motif-containing 72 (TRIM72; MG53)	<i>In vitro</i> and mouse studies suggest MG53 could help treat Duchenne muscular dystrophy (DMD) and other indications involving damage to cellular membranes. In mouse skeletal muscle fibers damaged by UV laser, MG53 pretreatment increased membrane resealing and repair compared with pretreatment using a control protein. In mouse models of DMD, MG53 pretreatment decreased circulating markers of muscle damage compared with pretreatment using vehicle. Ongoing work includes testing MG53 in rodent and pig models of myocardial infarction (MI), which also involves damage to cellular membranes.	Patented; licensed to TRIM-edicine Inc.; available for partnering	Weisleder, N. <i>et al. Sci. Transl. Med.</i> ; published online June 20, 2012; doi:10.1126/scitranslmed.3003921 Contact: Noah Weisleder, Robert Wood Johnson Medical School, Piscataway, N.J. e-mail: noah.weisleder@umdnj.edu Contact: Jianjie Ma, same affiliation as above e-mail: maj2@umdnj.edu
		SciBX 5(26); doi:10.1038/scibx.2012.680 Published online June 28, 2012		